Global Drugs for Non-Small Cell Lung Cancer Market Research Report 2024(Status and Outlook)
Report Overview
This report provides a deep insight into the global Drugs for Non-Small Cell Lung Cancer market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Drugs for Non-Small Cell Lung Cancer Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Drugs for Non-Small Cell Lung Cancer market in any manner.
Global Drugs for Non-Small Cell Lung Cancer Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
Market Segmentation (by Type)
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Market Segmentation (by Application)
Hospitals
Clinics
Other
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Drugs for Non-Small Cell Lung Cancer Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
This report provides a deep insight into the global Drugs for Non-Small Cell Lung Cancer market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Drugs for Non-Small Cell Lung Cancer Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Drugs for Non-Small Cell Lung Cancer market in any manner.
Global Drugs for Non-Small Cell Lung Cancer Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
Market Segmentation (by Type)
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Market Segmentation (by Application)
Hospitals
Clinics
Other
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Drugs for Non-Small Cell Lung Cancer Market
- Overview of the regional outlook of the Drugs for Non-Small Cell Lung Cancer Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Drugs for Non-Small Cell Lung Cancer Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Drugs for Non-Small Cell Lung Cancer
1.2 Key Market Segments
1.2.1 Drugs for Non-Small Cell Lung Cancer Segment by Type
1.2.2 Drugs for Non-Small Cell Lung Cancer Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Drugs for Non-Small Cell Lung Cancer Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET COMPETITIVE LANDSCAPE
3.1 Global Drugs for Non-Small Cell Lung Cancer Sales by Manufacturers (2019-2024)
3.2 Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Manufacturers (2019-2024)
3.3 Drugs for Non-Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Drugs for Non-Small Cell Lung Cancer Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Drugs for Non-Small Cell Lung Cancer Sales Sites, Area Served, Product Type
3.6 Drugs for Non-Small Cell Lung Cancer Market Competitive Situation and Trends
3.6.1 Drugs for Non-Small Cell Lung Cancer Market Concentration Rate
3.6.2 Global 5 and 10 Largest Drugs for Non-Small Cell Lung Cancer Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 DRUGS FOR NON-SMALL CELL LUNG CANCER INDUSTRY CHAIN ANALYSIS
4.1 Drugs for Non-Small Cell Lung Cancer Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Type (2019-2024)
6.3 Global Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type (2019-2024)
6.4 Global Drugs for Non-Small Cell Lung Cancer Price by Type (2019-2024)
7 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Drugs for Non-Small Cell Lung Cancer Market Sales by Application (2019-2024)
7.3 Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD) by Application (2019-2024)
7.4 Global Drugs for Non-Small Cell Lung Cancer Sales Growth Rate by Application (2019-2024)
8 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET SEGMENTATION BY REGION
8.1 Global Drugs for Non-Small Cell Lung Cancer Sales by Region
8.1.1 Global Drugs for Non-Small Cell Lung Cancer Sales by Region
8.1.2 Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Region
8.2 North America
8.2.1 North America Drugs for Non-Small Cell Lung Cancer Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Drugs for Non-Small Cell Lung Cancer Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Drugs for Non-Small Cell Lung Cancer Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Drugs for Non-Small Cell Lung Cancer Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Bristol-Myers Squibb
9.1.1 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Basic Information
9.1.2 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product Overview
9.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.1.4 Bristol-Myers Squibb Business Overview
9.1.5 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer SWOT Analysis
9.1.6 Bristol-Myers Squibb Recent Developments
9.2 GlaxoSmithKline
9.2.1 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Basic Information
9.2.2 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product Overview
9.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.2.4 GlaxoSmithKline Business Overview
9.2.5 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer SWOT Analysis
9.2.6 GlaxoSmithKline Recent Developments
9.3 Menarini
9.3.1 Menarini Drugs for Non-Small Cell Lung Cancer Basic Information
9.3.2 Menarini Drugs for Non-Small Cell Lung Cancer Product Overview
9.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.3.4 Menarini Drugs for Non-Small Cell Lung Cancer SWOT Analysis
9.3.5 Menarini Business Overview
9.3.6 Menarini Recent Developments
9.4 Sanofi
9.4.1 Sanofi Drugs for Non-Small Cell Lung Cancer Basic Information
9.4.2 Sanofi Drugs for Non-Small Cell Lung Cancer Product Overview
9.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.4.4 Sanofi Business Overview
9.4.5 Sanofi Recent Developments
9.5 Ziopharm Oncology
9.5.1 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Basic Information
9.5.2 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product Overview
9.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.5.4 Ziopharm Oncology Business Overview
9.5.5 Ziopharm Oncology Recent Developments
9.6 Alchemia
9.6.1 Alchemia Drugs for Non-Small Cell Lung Cancer Basic Information
9.6.2 Alchemia Drugs for Non-Small Cell Lung Cancer Product Overview
9.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.6.4 Alchemia Business Overview
9.6.5 Alchemia Recent Developments
9.7 Amgen
9.7.1 Amgen Drugs for Non-Small Cell Lung Cancer Basic Information
9.7.2 Amgen Drugs for Non-Small Cell Lung Cancer Product Overview
9.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.7.4 Amgen Business Overview
9.7.5 Amgen Recent Developments
9.8 Apotex
9.8.1 Apotex Drugs for Non-Small Cell Lung Cancer Basic Information
9.8.2 Apotex Drugs for Non-Small Cell Lung Cancer Product Overview
9.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.8.4 Apotex Business Overview
9.8.5 Apotex Recent Developments
9.9 BioMarin Pharmaceutical
9.9.1 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Basic Information
9.9.2 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product Overview
9.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.9.4 BioMarin Pharmaceutical Business Overview
9.9.5 BioMarin Pharmaceutical Recent Developments
9.10 CellAct Pharma
9.10.1 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Basic Information
9.10.2 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product Overview
9.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.10.4 CellAct Pharma Business Overview
9.10.5 CellAct Pharma Recent Developments
9.11 Cerulean Pharma
9.11.1 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Basic Information
9.11.2 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product Overview
9.11.3 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.11.4 Cerulean Pharma Business Overview
9.11.5 Cerulean Pharma Recent Developments
9.12 Cipla
9.12.1 Cipla Drugs for Non-Small Cell Lung Cancer Basic Information
9.12.2 Cipla Drugs for Non-Small Cell Lung Cancer Product Overview
9.12.3 Cipla Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.12.4 Cipla Business Overview
9.12.5 Cipla Recent Developments
9.13 Cornerstone Pharmaceuticals
9.13.1 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
9.13.2 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
9.13.3 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.13.4 Cornerstone Pharmaceuticals Business Overview
9.13.5 Cornerstone Pharmaceuticals Recent Developments
9.14 Curis
9.14.1 Curis Drugs for Non-Small Cell Lung Cancer Basic Information
9.14.2 Curis Drugs for Non-Small Cell Lung Cancer Product Overview
9.14.3 Curis Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.14.4 Curis Business Overview
9.14.5 Curis Recent Developments
9.15 CytRx
9.15.1 CytRx Drugs for Non-Small Cell Lung Cancer Basic Information
9.15.2 CytRx Drugs for Non-Small Cell Lung Cancer Product Overview
9.15.3 CytRx Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.15.4 CytRx Business Overview
9.15.5 CytRx Recent Developments
9.16 Eli Lilly
9.16.1 Eli Lilly Drugs for Non-Small Cell Lung Cancer Basic Information
9.16.2 Eli Lilly Drugs for Non-Small Cell Lung Cancer Product Overview
9.16.3 Eli Lilly Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.16.4 Eli Lilly Business Overview
9.16.5 Eli Lilly Recent Developments
9.17 Exelixis
9.17.1 Exelixis Drugs for Non-Small Cell Lung Cancer Basic Information
9.17.2 Exelixis Drugs for Non-Small Cell Lung Cancer Product Overview
9.17.3 Exelixis Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.17.4 Exelixis Business Overview
9.17.5 Exelixis Recent Developments
9.18 Fresenius Kabi
9.18.1 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Basic Information
9.18.2 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product Overview
9.18.3 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.18.4 Fresenius Kabi Business Overview
9.18.5 Fresenius Kabi Recent Developments
9.19 Genentech
9.19.1 Genentech Drugs for Non-Small Cell Lung Cancer Basic Information
9.19.2 Genentech Drugs for Non-Small Cell Lung Cancer Product Overview
9.19.3 Genentech Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.19.4 Genentech Business Overview
9.19.5 Genentech Recent Developments
9.20 Hikma Pharmaceuticals
9.20.1 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
9.20.2 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
9.20.3 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.20.4 Hikma Pharmaceuticals Business Overview
9.20.5 Hikma Pharmaceuticals Recent Developments
9.21 Hospira
9.21.1 Hospira Drugs for Non-Small Cell Lung Cancer Basic Information
9.21.2 Hospira Drugs for Non-Small Cell Lung Cancer Product Overview
9.21.3 Hospira Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.21.4 Hospira Business Overview
9.21.5 Hospira Recent Developments
9.22 Intas Pharmaceuticals
9.22.1 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
9.22.2 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
9.22.3 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.22.4 Intas Pharmaceuticals Business Overview
9.22.5 Intas Pharmaceuticals Recent Developments
9.23 Karyopharm Therapeutics
9.23.1 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Basic Information
9.23.2 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product Overview
9.23.3 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.23.4 Karyopharm Therapeutics Business Overview
9.23.5 Karyopharm Therapeutics Recent Developments
9.24 Kyowa Hakko Kirin
9.24.1 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Basic Information
9.24.2 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product Overview
9.24.3 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.24.4 Kyowa Hakko Kirin Business Overview
9.24.5 Kyowa Hakko Kirin Recent Developments
9.25 Ligand Pharmaceuticals
9.25.1 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
9.25.2 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
9.25.3 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.25.4 Ligand Pharmaceuticals Business Overview
9.25.5 Ligand Pharmaceuticals Recent Developments
10 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET FORECAST BY REGION
10.1 Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast
10.2 Global Drugs for Non-Small Cell Lung Cancer Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country
10.2.3 Asia Pacific Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Region
10.2.4 South America Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Drugs for Non-Small Cell Lung Cancer by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Drugs for Non-Small Cell Lung Cancer Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Drugs for Non-Small Cell Lung Cancer by Type (2025-2030)
11.1.2 Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Drugs for Non-Small Cell Lung Cancer by Type (2025-2030)
11.2 Global Drugs for Non-Small Cell Lung Cancer Market Forecast by Application (2025-2030)
11.2.1 Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) Forecast by Application
11.2.2 Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Drugs for Non-Small Cell Lung Cancer
1.2 Key Market Segments
1.2.1 Drugs for Non-Small Cell Lung Cancer Segment by Type
1.2.2 Drugs for Non-Small Cell Lung Cancer Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Drugs for Non-Small Cell Lung Cancer Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET COMPETITIVE LANDSCAPE
3.1 Global Drugs for Non-Small Cell Lung Cancer Sales by Manufacturers (2019-2024)
3.2 Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Manufacturers (2019-2024)
3.3 Drugs for Non-Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Drugs for Non-Small Cell Lung Cancer Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Drugs for Non-Small Cell Lung Cancer Sales Sites, Area Served, Product Type
3.6 Drugs for Non-Small Cell Lung Cancer Market Competitive Situation and Trends
3.6.1 Drugs for Non-Small Cell Lung Cancer Market Concentration Rate
3.6.2 Global 5 and 10 Largest Drugs for Non-Small Cell Lung Cancer Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 DRUGS FOR NON-SMALL CELL LUNG CANCER INDUSTRY CHAIN ANALYSIS
4.1 Drugs for Non-Small Cell Lung Cancer Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Type (2019-2024)
6.3 Global Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type (2019-2024)
6.4 Global Drugs for Non-Small Cell Lung Cancer Price by Type (2019-2024)
7 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Drugs for Non-Small Cell Lung Cancer Market Sales by Application (2019-2024)
7.3 Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD) by Application (2019-2024)
7.4 Global Drugs for Non-Small Cell Lung Cancer Sales Growth Rate by Application (2019-2024)
8 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET SEGMENTATION BY REGION
8.1 Global Drugs for Non-Small Cell Lung Cancer Sales by Region
8.1.1 Global Drugs for Non-Small Cell Lung Cancer Sales by Region
8.1.2 Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Region
8.2 North America
8.2.1 North America Drugs for Non-Small Cell Lung Cancer Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Drugs for Non-Small Cell Lung Cancer Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Drugs for Non-Small Cell Lung Cancer Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Drugs for Non-Small Cell Lung Cancer Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Bristol-Myers Squibb
9.1.1 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Basic Information
9.1.2 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product Overview
9.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.1.4 Bristol-Myers Squibb Business Overview
9.1.5 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer SWOT Analysis
9.1.6 Bristol-Myers Squibb Recent Developments
9.2 GlaxoSmithKline
9.2.1 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Basic Information
9.2.2 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product Overview
9.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.2.4 GlaxoSmithKline Business Overview
9.2.5 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer SWOT Analysis
9.2.6 GlaxoSmithKline Recent Developments
9.3 Menarini
9.3.1 Menarini Drugs for Non-Small Cell Lung Cancer Basic Information
9.3.2 Menarini Drugs for Non-Small Cell Lung Cancer Product Overview
9.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.3.4 Menarini Drugs for Non-Small Cell Lung Cancer SWOT Analysis
9.3.5 Menarini Business Overview
9.3.6 Menarini Recent Developments
9.4 Sanofi
9.4.1 Sanofi Drugs for Non-Small Cell Lung Cancer Basic Information
9.4.2 Sanofi Drugs for Non-Small Cell Lung Cancer Product Overview
9.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.4.4 Sanofi Business Overview
9.4.5 Sanofi Recent Developments
9.5 Ziopharm Oncology
9.5.1 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Basic Information
9.5.2 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product Overview
9.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.5.4 Ziopharm Oncology Business Overview
9.5.5 Ziopharm Oncology Recent Developments
9.6 Alchemia
9.6.1 Alchemia Drugs for Non-Small Cell Lung Cancer Basic Information
9.6.2 Alchemia Drugs for Non-Small Cell Lung Cancer Product Overview
9.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.6.4 Alchemia Business Overview
9.6.5 Alchemia Recent Developments
9.7 Amgen
9.7.1 Amgen Drugs for Non-Small Cell Lung Cancer Basic Information
9.7.2 Amgen Drugs for Non-Small Cell Lung Cancer Product Overview
9.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.7.4 Amgen Business Overview
9.7.5 Amgen Recent Developments
9.8 Apotex
9.8.1 Apotex Drugs for Non-Small Cell Lung Cancer Basic Information
9.8.2 Apotex Drugs for Non-Small Cell Lung Cancer Product Overview
9.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.8.4 Apotex Business Overview
9.8.5 Apotex Recent Developments
9.9 BioMarin Pharmaceutical
9.9.1 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Basic Information
9.9.2 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product Overview
9.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.9.4 BioMarin Pharmaceutical Business Overview
9.9.5 BioMarin Pharmaceutical Recent Developments
9.10 CellAct Pharma
9.10.1 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Basic Information
9.10.2 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product Overview
9.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.10.4 CellAct Pharma Business Overview
9.10.5 CellAct Pharma Recent Developments
9.11 Cerulean Pharma
9.11.1 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Basic Information
9.11.2 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product Overview
9.11.3 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.11.4 Cerulean Pharma Business Overview
9.11.5 Cerulean Pharma Recent Developments
9.12 Cipla
9.12.1 Cipla Drugs for Non-Small Cell Lung Cancer Basic Information
9.12.2 Cipla Drugs for Non-Small Cell Lung Cancer Product Overview
9.12.3 Cipla Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.12.4 Cipla Business Overview
9.12.5 Cipla Recent Developments
9.13 Cornerstone Pharmaceuticals
9.13.1 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
9.13.2 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
9.13.3 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.13.4 Cornerstone Pharmaceuticals Business Overview
9.13.5 Cornerstone Pharmaceuticals Recent Developments
9.14 Curis
9.14.1 Curis Drugs for Non-Small Cell Lung Cancer Basic Information
9.14.2 Curis Drugs for Non-Small Cell Lung Cancer Product Overview
9.14.3 Curis Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.14.4 Curis Business Overview
9.14.5 Curis Recent Developments
9.15 CytRx
9.15.1 CytRx Drugs for Non-Small Cell Lung Cancer Basic Information
9.15.2 CytRx Drugs for Non-Small Cell Lung Cancer Product Overview
9.15.3 CytRx Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.15.4 CytRx Business Overview
9.15.5 CytRx Recent Developments
9.16 Eli Lilly
9.16.1 Eli Lilly Drugs for Non-Small Cell Lung Cancer Basic Information
9.16.2 Eli Lilly Drugs for Non-Small Cell Lung Cancer Product Overview
9.16.3 Eli Lilly Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.16.4 Eli Lilly Business Overview
9.16.5 Eli Lilly Recent Developments
9.17 Exelixis
9.17.1 Exelixis Drugs for Non-Small Cell Lung Cancer Basic Information
9.17.2 Exelixis Drugs for Non-Small Cell Lung Cancer Product Overview
9.17.3 Exelixis Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.17.4 Exelixis Business Overview
9.17.5 Exelixis Recent Developments
9.18 Fresenius Kabi
9.18.1 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Basic Information
9.18.2 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product Overview
9.18.3 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.18.4 Fresenius Kabi Business Overview
9.18.5 Fresenius Kabi Recent Developments
9.19 Genentech
9.19.1 Genentech Drugs for Non-Small Cell Lung Cancer Basic Information
9.19.2 Genentech Drugs for Non-Small Cell Lung Cancer Product Overview
9.19.3 Genentech Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.19.4 Genentech Business Overview
9.19.5 Genentech Recent Developments
9.20 Hikma Pharmaceuticals
9.20.1 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
9.20.2 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
9.20.3 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.20.4 Hikma Pharmaceuticals Business Overview
9.20.5 Hikma Pharmaceuticals Recent Developments
9.21 Hospira
9.21.1 Hospira Drugs for Non-Small Cell Lung Cancer Basic Information
9.21.2 Hospira Drugs for Non-Small Cell Lung Cancer Product Overview
9.21.3 Hospira Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.21.4 Hospira Business Overview
9.21.5 Hospira Recent Developments
9.22 Intas Pharmaceuticals
9.22.1 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
9.22.2 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
9.22.3 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.22.4 Intas Pharmaceuticals Business Overview
9.22.5 Intas Pharmaceuticals Recent Developments
9.23 Karyopharm Therapeutics
9.23.1 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Basic Information
9.23.2 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product Overview
9.23.3 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.23.4 Karyopharm Therapeutics Business Overview
9.23.5 Karyopharm Therapeutics Recent Developments
9.24 Kyowa Hakko Kirin
9.24.1 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Basic Information
9.24.2 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product Overview
9.24.3 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.24.4 Kyowa Hakko Kirin Business Overview
9.24.5 Kyowa Hakko Kirin Recent Developments
9.25 Ligand Pharmaceuticals
9.25.1 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
9.25.2 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
9.25.3 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Market Performance
9.25.4 Ligand Pharmaceuticals Business Overview
9.25.5 Ligand Pharmaceuticals Recent Developments
10 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET FORECAST BY REGION
10.1 Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast
10.2 Global Drugs for Non-Small Cell Lung Cancer Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country
10.2.3 Asia Pacific Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Region
10.2.4 South America Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Drugs for Non-Small Cell Lung Cancer by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Drugs for Non-Small Cell Lung Cancer Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Drugs for Non-Small Cell Lung Cancer by Type (2025-2030)
11.1.2 Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Drugs for Non-Small Cell Lung Cancer by Type (2025-2030)
11.2 Global Drugs for Non-Small Cell Lung Cancer Market Forecast by Application (2025-2030)
11.2.1 Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) Forecast by Application
11.2.2 Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Drugs for Non-Small Cell Lung Cancer Market Size Comparison by Region (M USD)
Table 5. Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Drugs for Non-Small Cell Lung Cancer Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Non-Small Cell Lung Cancer as of 2022)
Table 10. Global Market Drugs for Non-Small Cell Lung Cancer Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Drugs for Non-Small Cell Lung Cancer Sales Sites and Area Served
Table 12. Manufacturers Drugs for Non-Small Cell Lung Cancer Product Type
Table 13. Global Drugs for Non-Small Cell Lung Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Drugs for Non-Small Cell Lung Cancer
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Drugs for Non-Small Cell Lung Cancer Market Challenges
Table 22. Global Drugs for Non-Small Cell Lung Cancer Sales by Type (K Units)
Table 23. Global Drugs for Non-Small Cell Lung Cancer Market Size by Type (M USD)
Table 24. Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) by Type (2019-2024)
Table 25. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Type (2019-2024)
Table 26. Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD) by Type (2019-2024)
Table 27. Global Drugs for Non-Small Cell Lung Cancer Market Size Share by Type (2019-2024)
Table 28. Global Drugs for Non-Small Cell Lung Cancer Price (USD/Unit) by Type (2019-2024)
Table 29. Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) by Application
Table 30. Global Drugs for Non-Small Cell Lung Cancer Market Size by Application
Table 31. Global Drugs for Non-Small Cell Lung Cancer Sales by Application (2019-2024) & (K Units)
Table 32. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Application (2019-2024)
Table 33. Global Drugs for Non-Small Cell Lung Cancer Sales by Application (2019-2024) & (M USD)
Table 34. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application (2019-2024)
Table 35. Global Drugs for Non-Small Cell Lung Cancer Sales Growth Rate by Application (2019-2024)
Table 36. Global Drugs for Non-Small Cell Lung Cancer Sales by Region (2019-2024) & (K Units)
Table 37. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Region (2019-2024)
Table 38. North America Drugs for Non-Small Cell Lung Cancer Sales by Country (2019-2024) & (K Units)
Table 39. Europe Drugs for Non-Small Cell Lung Cancer Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales by Region (2019-2024) & (K Units)
Table 41. South America Drugs for Non-Small Cell Lung Cancer Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Sales by Region (2019-2024) & (K Units)
Table 43. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Basic Information
Table 44. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product Overview
Table 45. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Bristol-Myers Squibb Business Overview
Table 47. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer SWOT Analysis
Table 48. Bristol-Myers Squibb Recent Developments
Table 49. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Basic Information
Table 50. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product Overview
Table 51. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. GlaxoSmithKline Business Overview
Table 53. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer SWOT Analysis
Table 54. GlaxoSmithKline Recent Developments
Table 55. Menarini Drugs for Non-Small Cell Lung Cancer Basic Information
Table 56. Menarini Drugs for Non-Small Cell Lung Cancer Product Overview
Table 57. Menarini Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Menarini Drugs for Non-Small Cell Lung Cancer SWOT Analysis
Table 59. Menarini Business Overview
Table 60. Menarini Recent Developments
Table 61. Sanofi Drugs for Non-Small Cell Lung Cancer Basic Information
Table 62. Sanofi Drugs for Non-Small Cell Lung Cancer Product Overview
Table 63. Sanofi Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Sanofi Business Overview
Table 65. Sanofi Recent Developments
Table 66. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Basic Information
Table 67. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product Overview
Table 68. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Ziopharm Oncology Business Overview
Table 70. Ziopharm Oncology Recent Developments
Table 71. Alchemia Drugs for Non-Small Cell Lung Cancer Basic Information
Table 72. Alchemia Drugs for Non-Small Cell Lung Cancer Product Overview
Table 73. Alchemia Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Alchemia Business Overview
Table 75. Alchemia Recent Developments
Table 76. Amgen Drugs for Non-Small Cell Lung Cancer Basic Information
Table 77. Amgen Drugs for Non-Small Cell Lung Cancer Product Overview
Table 78. Amgen Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Amgen Business Overview
Table 80. Amgen Recent Developments
Table 81. Apotex Drugs for Non-Small Cell Lung Cancer Basic Information
Table 82. Apotex Drugs for Non-Small Cell Lung Cancer Product Overview
Table 83. Apotex Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Apotex Business Overview
Table 85. Apotex Recent Developments
Table 86. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Basic Information
Table 87. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product Overview
Table 88. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. BioMarin Pharmaceutical Business Overview
Table 90. BioMarin Pharmaceutical Recent Developments
Table 91. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Basic Information
Table 92. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product Overview
Table 93. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. CellAct Pharma Business Overview
Table 95. CellAct Pharma Recent Developments
Table 96. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Basic Information
Table 97. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product Overview
Table 98. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Cerulean Pharma Business Overview
Table 100. Cerulean Pharma Recent Developments
Table 101. Cipla Drugs for Non-Small Cell Lung Cancer Basic Information
Table 102. Cipla Drugs for Non-Small Cell Lung Cancer Product Overview
Table 103. Cipla Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Cipla Business Overview
Table 105. Cipla Recent Developments
Table 106. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
Table 107. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
Table 108. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Cornerstone Pharmaceuticals Business Overview
Table 110. Cornerstone Pharmaceuticals Recent Developments
Table 111. Curis Drugs for Non-Small Cell Lung Cancer Basic Information
Table 112. Curis Drugs for Non-Small Cell Lung Cancer Product Overview
Table 113. Curis Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Curis Business Overview
Table 115. Curis Recent Developments
Table 116. CytRx Drugs for Non-Small Cell Lung Cancer Basic Information
Table 117. CytRx Drugs for Non-Small Cell Lung Cancer Product Overview
Table 118. CytRx Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. CytRx Business Overview
Table 120. CytRx Recent Developments
Table 121. Eli Lilly Drugs for Non-Small Cell Lung Cancer Basic Information
Table 122. Eli Lilly Drugs for Non-Small Cell Lung Cancer Product Overview
Table 123. Eli Lilly Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Eli Lilly Business Overview
Table 125. Eli Lilly Recent Developments
Table 126. Exelixis Drugs for Non-Small Cell Lung Cancer Basic Information
Table 127. Exelixis Drugs for Non-Small Cell Lung Cancer Product Overview
Table 128. Exelixis Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Exelixis Business Overview
Table 130. Exelixis Recent Developments
Table 131. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Basic Information
Table 132. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product Overview
Table 133. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Fresenius Kabi Business Overview
Table 135. Fresenius Kabi Recent Developments
Table 136. Genentech Drugs for Non-Small Cell Lung Cancer Basic Information
Table 137. Genentech Drugs for Non-Small Cell Lung Cancer Product Overview
Table 138. Genentech Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 139. Genentech Business Overview
Table 140. Genentech Recent Developments
Table 141. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
Table 142. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
Table 143. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 144. Hikma Pharmaceuticals Business Overview
Table 145. Hikma Pharmaceuticals Recent Developments
Table 146. Hospira Drugs for Non-Small Cell Lung Cancer Basic Information
Table 147. Hospira Drugs for Non-Small Cell Lung Cancer Product Overview
Table 148. Hospira Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 149. Hospira Business Overview
Table 150. Hospira Recent Developments
Table 151. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
Table 152. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
Table 153. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 154. Intas Pharmaceuticals Business Overview
Table 155. Intas Pharmaceuticals Recent Developments
Table 156. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Basic Information
Table 157. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product Overview
Table 158. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 159. Karyopharm Therapeutics Business Overview
Table 160. Karyopharm Therapeutics Recent Developments
Table 161. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Basic Information
Table 162. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product Overview
Table 163. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 164. Kyowa Hakko Kirin Business Overview
Table 165. Kyowa Hakko Kirin Recent Developments
Table 166. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
Table 167. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
Table 168. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 169. Ligand Pharmaceuticals Business Overview
Table 170. Ligand Pharmaceuticals Recent Developments
Table 171. Global Drugs for Non-Small Cell Lung Cancer Sales Forecast by Region (2025-2030) & (K Units)
Table 172. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Region (2025-2030) & (M USD)
Table 173. North America Drugs for Non-Small Cell Lung Cancer Sales Forecast by Country (2025-2030) & (K Units)
Table 174. North America Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 175. Europe Drugs for Non-Small Cell Lung Cancer Sales Forecast by Country (2025-2030) & (K Units)
Table 176. Europe Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 177. Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales Forecast by Region (2025-2030) & (K Units)
Table 178. Asia Pacific Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Region (2025-2030) & (M USD)
Table 179. South America Drugs for Non-Small Cell Lung Cancer Sales Forecast by Country (2025-2030) & (K Units)
Table 180. South America Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 181. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Consumption Forecast by Country (2025-2030) & (Units)
Table 182. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 183. Global Drugs for Non-Small Cell Lung Cancer Sales Forecast by Type (2025-2030) & (K Units)
Table 184. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Type (2025-2030) & (M USD)
Table 185. Global Drugs for Non-Small Cell Lung Cancer Price Forecast by Type (2025-2030) & (USD/Unit)
Table 186. Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) Forecast by Application (2025-2030)
Table 187. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Drugs for Non-Small Cell Lung Cancer Market Size Comparison by Region (M USD)
Table 5. Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Drugs for Non-Small Cell Lung Cancer Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Non-Small Cell Lung Cancer as of 2022)
Table 10. Global Market Drugs for Non-Small Cell Lung Cancer Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Drugs for Non-Small Cell Lung Cancer Sales Sites and Area Served
Table 12. Manufacturers Drugs for Non-Small Cell Lung Cancer Product Type
Table 13. Global Drugs for Non-Small Cell Lung Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Drugs for Non-Small Cell Lung Cancer
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Drugs for Non-Small Cell Lung Cancer Market Challenges
Table 22. Global Drugs for Non-Small Cell Lung Cancer Sales by Type (K Units)
Table 23. Global Drugs for Non-Small Cell Lung Cancer Market Size by Type (M USD)
Table 24. Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) by Type (2019-2024)
Table 25. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Type (2019-2024)
Table 26. Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD) by Type (2019-2024)
Table 27. Global Drugs for Non-Small Cell Lung Cancer Market Size Share by Type (2019-2024)
Table 28. Global Drugs for Non-Small Cell Lung Cancer Price (USD/Unit) by Type (2019-2024)
Table 29. Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) by Application
Table 30. Global Drugs for Non-Small Cell Lung Cancer Market Size by Application
Table 31. Global Drugs for Non-Small Cell Lung Cancer Sales by Application (2019-2024) & (K Units)
Table 32. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Application (2019-2024)
Table 33. Global Drugs for Non-Small Cell Lung Cancer Sales by Application (2019-2024) & (M USD)
Table 34. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application (2019-2024)
Table 35. Global Drugs for Non-Small Cell Lung Cancer Sales Growth Rate by Application (2019-2024)
Table 36. Global Drugs for Non-Small Cell Lung Cancer Sales by Region (2019-2024) & (K Units)
Table 37. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Region (2019-2024)
Table 38. North America Drugs for Non-Small Cell Lung Cancer Sales by Country (2019-2024) & (K Units)
Table 39. Europe Drugs for Non-Small Cell Lung Cancer Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales by Region (2019-2024) & (K Units)
Table 41. South America Drugs for Non-Small Cell Lung Cancer Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Sales by Region (2019-2024) & (K Units)
Table 43. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Basic Information
Table 44. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product Overview
Table 45. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Bristol-Myers Squibb Business Overview
Table 47. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer SWOT Analysis
Table 48. Bristol-Myers Squibb Recent Developments
Table 49. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Basic Information
Table 50. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product Overview
Table 51. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. GlaxoSmithKline Business Overview
Table 53. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer SWOT Analysis
Table 54. GlaxoSmithKline Recent Developments
Table 55. Menarini Drugs for Non-Small Cell Lung Cancer Basic Information
Table 56. Menarini Drugs for Non-Small Cell Lung Cancer Product Overview
Table 57. Menarini Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Menarini Drugs for Non-Small Cell Lung Cancer SWOT Analysis
Table 59. Menarini Business Overview
Table 60. Menarini Recent Developments
Table 61. Sanofi Drugs for Non-Small Cell Lung Cancer Basic Information
Table 62. Sanofi Drugs for Non-Small Cell Lung Cancer Product Overview
Table 63. Sanofi Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Sanofi Business Overview
Table 65. Sanofi Recent Developments
Table 66. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Basic Information
Table 67. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product Overview
Table 68. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Ziopharm Oncology Business Overview
Table 70. Ziopharm Oncology Recent Developments
Table 71. Alchemia Drugs for Non-Small Cell Lung Cancer Basic Information
Table 72. Alchemia Drugs for Non-Small Cell Lung Cancer Product Overview
Table 73. Alchemia Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Alchemia Business Overview
Table 75. Alchemia Recent Developments
Table 76. Amgen Drugs for Non-Small Cell Lung Cancer Basic Information
Table 77. Amgen Drugs for Non-Small Cell Lung Cancer Product Overview
Table 78. Amgen Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Amgen Business Overview
Table 80. Amgen Recent Developments
Table 81. Apotex Drugs for Non-Small Cell Lung Cancer Basic Information
Table 82. Apotex Drugs for Non-Small Cell Lung Cancer Product Overview
Table 83. Apotex Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Apotex Business Overview
Table 85. Apotex Recent Developments
Table 86. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Basic Information
Table 87. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product Overview
Table 88. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. BioMarin Pharmaceutical Business Overview
Table 90. BioMarin Pharmaceutical Recent Developments
Table 91. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Basic Information
Table 92. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product Overview
Table 93. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. CellAct Pharma Business Overview
Table 95. CellAct Pharma Recent Developments
Table 96. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Basic Information
Table 97. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product Overview
Table 98. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Cerulean Pharma Business Overview
Table 100. Cerulean Pharma Recent Developments
Table 101. Cipla Drugs for Non-Small Cell Lung Cancer Basic Information
Table 102. Cipla Drugs for Non-Small Cell Lung Cancer Product Overview
Table 103. Cipla Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Cipla Business Overview
Table 105. Cipla Recent Developments
Table 106. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
Table 107. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
Table 108. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Cornerstone Pharmaceuticals Business Overview
Table 110. Cornerstone Pharmaceuticals Recent Developments
Table 111. Curis Drugs for Non-Small Cell Lung Cancer Basic Information
Table 112. Curis Drugs for Non-Small Cell Lung Cancer Product Overview
Table 113. Curis Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Curis Business Overview
Table 115. Curis Recent Developments
Table 116. CytRx Drugs for Non-Small Cell Lung Cancer Basic Information
Table 117. CytRx Drugs for Non-Small Cell Lung Cancer Product Overview
Table 118. CytRx Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. CytRx Business Overview
Table 120. CytRx Recent Developments
Table 121. Eli Lilly Drugs for Non-Small Cell Lung Cancer Basic Information
Table 122. Eli Lilly Drugs for Non-Small Cell Lung Cancer Product Overview
Table 123. Eli Lilly Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Eli Lilly Business Overview
Table 125. Eli Lilly Recent Developments
Table 126. Exelixis Drugs for Non-Small Cell Lung Cancer Basic Information
Table 127. Exelixis Drugs for Non-Small Cell Lung Cancer Product Overview
Table 128. Exelixis Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Exelixis Business Overview
Table 130. Exelixis Recent Developments
Table 131. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Basic Information
Table 132. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product Overview
Table 133. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Fresenius Kabi Business Overview
Table 135. Fresenius Kabi Recent Developments
Table 136. Genentech Drugs for Non-Small Cell Lung Cancer Basic Information
Table 137. Genentech Drugs for Non-Small Cell Lung Cancer Product Overview
Table 138. Genentech Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 139. Genentech Business Overview
Table 140. Genentech Recent Developments
Table 141. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
Table 142. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
Table 143. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 144. Hikma Pharmaceuticals Business Overview
Table 145. Hikma Pharmaceuticals Recent Developments
Table 146. Hospira Drugs for Non-Small Cell Lung Cancer Basic Information
Table 147. Hospira Drugs for Non-Small Cell Lung Cancer Product Overview
Table 148. Hospira Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 149. Hospira Business Overview
Table 150. Hospira Recent Developments
Table 151. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
Table 152. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
Table 153. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 154. Intas Pharmaceuticals Business Overview
Table 155. Intas Pharmaceuticals Recent Developments
Table 156. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Basic Information
Table 157. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product Overview
Table 158. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 159. Karyopharm Therapeutics Business Overview
Table 160. Karyopharm Therapeutics Recent Developments
Table 161. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Basic Information
Table 162. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product Overview
Table 163. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 164. Kyowa Hakko Kirin Business Overview
Table 165. Kyowa Hakko Kirin Recent Developments
Table 166. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information
Table 167. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview
Table 168. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 169. Ligand Pharmaceuticals Business Overview
Table 170. Ligand Pharmaceuticals Recent Developments
Table 171. Global Drugs for Non-Small Cell Lung Cancer Sales Forecast by Region (2025-2030) & (K Units)
Table 172. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Region (2025-2030) & (M USD)
Table 173. North America Drugs for Non-Small Cell Lung Cancer Sales Forecast by Country (2025-2030) & (K Units)
Table 174. North America Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 175. Europe Drugs for Non-Small Cell Lung Cancer Sales Forecast by Country (2025-2030) & (K Units)
Table 176. Europe Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 177. Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales Forecast by Region (2025-2030) & (K Units)
Table 178. Asia Pacific Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Region (2025-2030) & (M USD)
Table 179. South America Drugs for Non-Small Cell Lung Cancer Sales Forecast by Country (2025-2030) & (K Units)
Table 180. South America Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 181. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Consumption Forecast by Country (2025-2030) & (Units)
Table 182. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country (2025-2030) & (M USD)
Table 183. Global Drugs for Non-Small Cell Lung Cancer Sales Forecast by Type (2025-2030) & (K Units)
Table 184. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Type (2025-2030) & (M USD)
Table 185. Global Drugs for Non-Small Cell Lung Cancer Price Forecast by Type (2025-2030) & (USD/Unit)
Table 186. Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) Forecast by Application (2025-2030)
Table 187. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Drugs for Non-Small Cell Lung Cancer
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD), 2019-2030
Figure 5. Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD) (2019-2030)
Figure 6. Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Drugs for Non-Small Cell Lung Cancer Market Size by Country (M USD)
Figure 11. Drugs for Non-Small Cell Lung Cancer Sales Share by Manufacturers in 2023
Figure 12. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Manufacturers in 2023
Figure 13. Drugs for Non-Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Drugs for Non-Small Cell Lung Cancer Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Drugs for Non-Small Cell Lung Cancer Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Drugs for Non-Small Cell Lung Cancer Market Share by Type
Figure 18. Sales Market Share of Drugs for Non-Small Cell Lung Cancer by Type (2019-2024)
Figure 19. Sales Market Share of Drugs for Non-Small Cell Lung Cancer by Type in 2023
Figure 20. Market Size Share of Drugs for Non-Small Cell Lung Cancer by Type (2019-2024)
Figure 21. Market Size Market Share of Drugs for Non-Small Cell Lung Cancer by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application
Figure 24. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Application (2019-2024)
Figure 25. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Application in 2023
Figure 26. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application (2019-2024)
Figure 27. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application in 2023
Figure 28. Global Drugs for Non-Small Cell Lung Cancer Sales Growth Rate by Application (2019-2024)
Figure 29. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Region (2019-2024)
Figure 30. North America Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Drugs for Non-Small Cell Lung Cancer Sales Market Share by Country in 2023
Figure 32. U.S. Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Drugs for Non-Small Cell Lung Cancer Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Drugs for Non-Small Cell Lung Cancer Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Drugs for Non-Small Cell Lung Cancer Sales Market Share by Country in 2023
Figure 37. Germany Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales Market Share by Region in 2023
Figure 44. China Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (K Units)
Figure 50. South America Drugs for Non-Small Cell Lung Cancer Sales Market Share by Country in 2023
Figure 51. Brazil Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Drugs for Non-Small Cell Lung Cancer Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Drugs for Non-Small Cell Lung Cancer Market Share Forecast by Type (2025-2030)
Figure 65. Global Drugs for Non-Small Cell Lung Cancer Sales Forecast by Application (2025-2030)
Figure 66. Global Drugs for Non-Small Cell Lung Cancer Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Drugs for Non-Small Cell Lung Cancer
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD), 2019-2030
Figure 5. Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD) (2019-2030)
Figure 6. Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Drugs for Non-Small Cell Lung Cancer Market Size by Country (M USD)
Figure 11. Drugs for Non-Small Cell Lung Cancer Sales Share by Manufacturers in 2023
Figure 12. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Manufacturers in 2023
Figure 13. Drugs for Non-Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Drugs for Non-Small Cell Lung Cancer Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Drugs for Non-Small Cell Lung Cancer Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Drugs for Non-Small Cell Lung Cancer Market Share by Type
Figure 18. Sales Market Share of Drugs for Non-Small Cell Lung Cancer by Type (2019-2024)
Figure 19. Sales Market Share of Drugs for Non-Small Cell Lung Cancer by Type in 2023
Figure 20. Market Size Share of Drugs for Non-Small Cell Lung Cancer by Type (2019-2024)
Figure 21. Market Size Market Share of Drugs for Non-Small Cell Lung Cancer by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application
Figure 24. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Application (2019-2024)
Figure 25. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Application in 2023
Figure 26. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application (2019-2024)
Figure 27. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application in 2023
Figure 28. Global Drugs for Non-Small Cell Lung Cancer Sales Growth Rate by Application (2019-2024)
Figure 29. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Region (2019-2024)
Figure 30. North America Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Drugs for Non-Small Cell Lung Cancer Sales Market Share by Country in 2023
Figure 32. U.S. Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Drugs for Non-Small Cell Lung Cancer Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Drugs for Non-Small Cell Lung Cancer Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Drugs for Non-Small Cell Lung Cancer Sales Market Share by Country in 2023
Figure 37. Germany Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales Market Share by Region in 2023
Figure 44. China Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (K Units)
Figure 50. South America Drugs for Non-Small Cell Lung Cancer Sales Market Share by Country in 2023
Figure 51. Brazil Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Drugs for Non-Small Cell Lung Cancer Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Drugs for Non-Small Cell Lung Cancer Market Share Forecast by Type (2025-2030)
Figure 65. Global Drugs for Non-Small Cell Lung Cancer Sales Forecast by Application (2025-2030)
Figure 66. Global Drugs for Non-Small Cell Lung Cancer Market Share Forecast by Application (2025-2030)
